TIDES: Oligonucleotides and Peptide Therapeutics

It was great to be part of TIDES: Oligonucleotides and Peptide Therapeutics Europe 2026 in Amsterdam this week.

Representing Harness Therapeutics, Giulia Furlan joined scientists and industry experts to explore the latest developments in oligonucleotide and peptide therapeutics.

As RNA-targeted approaches continue to evolve, events like TIDES provide an opportunity to exchange scientific insights, explore emerging developments and discuss the challenges involved in translating research into new treatments.

Thank you to everyone who contributed to the discussions.

#TIDESEurope #OligonucleotideTherapeutics #RNATherapeutics #Biotechnology

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Parkinson’s Disease

Discover more

Our news

June 2026

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson's Disease Programme

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

View all